TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information
Supplier Page
RBC8
2 mg
| 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information
Supplier Page
RBC8
10 mg
| 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information
Supplier Page
RBC8
25 mg
| 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information
Supplier Page
RBC8
50 mg
| 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information
Supplier Page
TargetMol
Retapamulin, a Pleuromutilin Antibacterial, binds to both E. coli and S. aureus ribosomes with similar potencies (Kd: 3 nM).
More Information
Supplier Page
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information
Supplier Page
TargetMol
Clinofibrate
100 mg
| Purity Not Available
TargetMol
Clinofibrate(IC50 of 0.47 mM), a lipid-lowering agent, inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR). It is utilized to control high cholesterol and triacylglyceride levels in the blood.
More Information
Supplier Page
Clinofibrate
25 mg
| Purity Not Available
TargetMol
Clinofibrate(IC50 of 0.47 mM), a lipid-lowering agent, inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR). It is utilized to control high cholesterol and triacylglyceride levels in the blood.
More Information
Supplier Page